newsfilter
← Latest News
GlobeNewswire·

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

HUMA
  • Humacyte announced that the FY 2026 U.S. Department of Defense Appropriations Act includes dedicated funding to evaluate & incorporate biologic vascular repair technologies for treating traumatic vascular injuries in service members.
  • The FY 2026 NDAA report language directs the DoD to integrate FDA-approved breakthrough vascular repair technologies to provide off-the-shelf, biologically active conduits when autologous vein harvesting is not feasible.
  • Symvess is the only FDA-approved human-derived bioengineered blood vessel, indicated for adults with extremity arterial injuries requiring urgent revascularization to avoid limb loss when autologous vein grafts are not feasible.
  • CEO Laura Niklason stated that the federal investment ensures soldiers have access to cutting-edge treatments, citing a humanitarian program in Ukraine where 16 patients treated with Symvess achieved 100% survival, zero amputations, & zero infections despite serious wartime injuries.
  • Symvess carries a Boxed Warning for graft failure, which can result in life-threatening hemorrhage due to mid-graft rupture or anastomotic failure.
  • Contraindications include patients unable to undergo long-term antiplatelet therapy, such as aspirin or clopidogrel, after acute injury resolution.
  • Warnings & precautions highlight risks of graft rupture, anastomotic failure occurring within 36 days post-implantation, thrombosis, & potential transmission of infectious diseases.
  • The most common adverse reactions (occurring at ≥ 10%) were vascular graft thrombosis, pyrexia (fever), & pain.
  • Humacyte's Biologics License Application for Symvess was approved by the FDA in December 2024 for the vascular trauma indication.
  • Additional ATEV candidates for hemodialysis access & peripheral artery disease have received RMAT & Fast Track designations, while preclinical development continues for coronary artery bypass, pediatric heart surgery, & type 1 diabetes treatment.